Findings of Research Misconduct, 49597-49598 [2022-17264]
Download as PDF
Federal Register / Vol. 87, No. 154 / Thursday, August 11, 2022 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
Findings of research
misconduct have been made against
Stuart G. Jarrett, Ph.D. (Respondent),
former research-track assistant
professor, Department of Toxicology
and Cancer Biology and Markey Cancer
Center, University of Kentucky (UK)
College of Medicine. Respondent
engaged in research misconduct under
42 CFR part 93 in research supported by
U.S. Public Health Service (PHS) funds,
specifically National Cancer Institute
(NCI), National Institutes of Health
(NIH), grants R01 CA131075 and T32
CA165990, National Center for
Advancing Translational Sciences
(NCATS), NIH, grant UL1 TR000117,
and National Institute of Environmental
Health Sciences (NIEHS), NIH, grant
T32 ES007266. The administrative
actions, including debarment for a
period of four (4) years, were
implemented beginning on July 18,
2022, and are detailed below.
FOR FURTHER INFORMATION CONTACT:
Wanda K. Jones, Dr.P.H., Acting
Director, Office of Research Integrity,
1101 Wootton Parkway, Suite 240,
Rockville, MD 20852, (240) 453–8200.
SUPPLEMENTARY INFORMATION: Notice is
hereby given that the Office of Research
Integrity (ORI) has taken final action in
the following case:
Stuart G. Jarrett, Ph.D., University of
Kentucky: Based on the evidence and
findings of an investigation conducted
by UK, ORI’s oversight review of UK’s
investigation, and additional evidence
obtained and analysis conducted by ORI
during its oversight review, ORI found
that Dr. Stuart G. Jarrett, former
research-track assistant professor,
Department of Toxicology and Cancer
Biology and Markey Cancer Center, UK
College of Medicine, engaged in
research misconduct under 42 CFR part
93 in research supported by PHS funds,
specifically NCI, NIH, grants R01
CA131075 and T32 CA165990, NCATS,
NIH, grant UL1 TR000117, and NIEHS,
NIH, grant T32 ES007266.
ORI found by a preponderance of the
evidence that Respondent intentionally,
knowingly, or recklessly falsified and/or
fabricated Western blot and histological
image data related to mechanisms of
melanoma protection by reusing,
relabeling, and manipulating images or
using blank panels to falsely report data
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
17:49 Aug 10, 2022
Jkt 256001
in twenty-eight (28) figures included in
four (4) PHS-supported published
papers, one (1) funded PHS grant
application, and two (2) unfunded PHS
grant applications. ORI found that these
acts constitute a significant departure
from accepted practices of the relevant
research community. The affected
papers and grant applications are:
• PKA-mediated phosphorylation of
ATR promotes recruitment of XPA to
UV-induced DNA damage. Mol. Cell
2014 Jun 19;54(6):999–1011; doi:
10.1016/j.molcel.2014.05.030
(hereafter referred to as ‘‘Mol. Cell
2014’’).
• AKAP12 mediates PKA-induced
phosphorylation of ATR to enhance
nucleotide excision repair. Nucleic
Acids Res. 2016 Dec 15;44(22):10711–
26; doi: 10.1093/nar/gkw871
(hereafter referred to as ‘‘Nucleic
Acids Res. 2016’’). Retraction in:
Nucleic Acids Res. 2020 Nov 18;
48(20):11814; doi: 10.1093/nar/
gkaa984.
• Sirtuin 1-mediated deacetylation of
XPA DNA repair protein enhances its
interaction with ATR protein and
promotes cAMP-induced DNA repair
of UV damage. J. Biol. Chem. 2018
Dec 7; 293(49): 19025–37; doi:
10.1074/jbc.RA118.003940 (hereafter
referred to as ‘‘JBC 2018’’). Retraction
in: J. Biol. Chem. 2021 Jan–
Jun;296:100185; doi: 10.1016/
j.jbc.2020.100185.
• The melanocortin signaling cAMP
axis accelerates repair and reduces
mutagenesis of platinum-induced
DNA damage. Sci. Rep. 2017 Sep
15;7(1):11708; doi: 10.1038/s41598–
017–12056–5 (hereafter referred to as
‘‘Sci. Rep. 2017’’). Retraction in: Sci.
Rep. 2021 Jan 7;11(1):847; doi:
10.1038/s41598–020–80467–y.
• R01 CA131075–06, ‘‘Defining the
contribution of ATR to MC1Renhanced DNA repair in
melanocytes,’’ submitted to NCI, NIH,
on July 1, 2014 (not funded).
• R01 CA131075–06A1, ‘‘Defining the
contribution of ATR to MC1Renhanced DNA repair in
melanocytes,’’ submitted to NCI, NIH,
on March 2, 2015, Funded Project
Dates: July 1, 2010–March 31, 2022.
• R01 CA207312–01, ‘‘Defining
mechanisms of MC1R-enhanced
nucleotide excision repair in
melanocytes,’’ submitted to NCI, NIH,
on October 1, 2015 (not funded).
Specifically, ORI found by a
preponderance of the evidence that
Respondent engaged in research
misconduct by intentionally,
knowingly, or recklessly falsifying and/
or fabricating:
PO 00000
Frm 00020
Fmt 4703
Sfmt 4703
49597
• Western blot images in Figures 7D
and 7E of Mol. Cell 2014 by reusing,
manipulating, and relabeling an image
to falsely represent different
experiments in UV-untreated cells in
Figure 7D and in UV-treated cells in
Figure 7E
• Western blot images in Supplemental
Figure 3C of Mol. Cell. 2014 by
reusing, manipulating, and relabeling
a blot panel image to falsely represent
different experiments involving [6–4]photoproducts and XPA
• confocal microscopic images of
melanocytes in Figure 1C of Nucleic
Acids Res. 2016 by inserting a blank
image panel to falsely represent the
absence of proximity ligation assay
(PLA) signal in a negative control
experiment when the original image
showed PLA signal
• confocal microscopic images of
melanocytes in Figure 5B of Nucleic
Acids Res. 2016, by inserting blank
image panels to falsely represent UVuntreated control experiments, and
the quantification reported in Figure
5C that was derived from falsified
and/or fabricated images in Figure 5B
• confocal microscopic images of
melanocytes in Figure 6A of Nucleic
Acids Res. 2016, by inserting blank
image panels to falsely represent the
absence of PLA signal in negative
control experiments when the original
images showed PLA signal, and the
quantification reported in Figure 6C
that was derived from falsified and/or
fabricated images in Figure 6A
• confocal microscopic images of
melanocytes in Figure 6B of Nucleic
Acids Res. 2016, by inserting blank
image panels to falsely represent UVuntreated control experiments, and
the quantification reported in Figure
6C that was derived from falsified
and/or fabricated images in Figure 6B
• confocal microscopic images of
melanocytes in Figure 6D of Nucleic
Acids Res. 2016, by inserting blank
image panels to falsely represent no
PLA signal in control experiments
when the original images showed PLA
signal, and the quantification reported
in Figure 6F that was derived from
falsified and/or fabricated images in
Figure 6D
• confocal microscopic images of
melanocytes in Figure 6E of Nucleic
Acids Res. 2016, by inserting blank
image panels to falsely represent UVuntreated control experiments, and
the quantification reported in Figure
6F that was derived from falsified
and/or fabricated images in Figure 6E
• confocal microscopic images of
melanocytes in Figure 6G of Nucleic
Acids Res. 2016 by inserting blank
image panels to falsely represent the
E:\FR\FM\11AUN1.SGM
11AUN1
49598
•
•
•
•
•
lotter on DSK11XQN23PROD with NOTICES1
•
Federal Register / Vol. 87, No. 154 / Thursday, August 11, 2022 / Notices
absence of nuclear localization of
XPA, AKAP12, and ATR–pS435 in
unirradiated cells transfected with
wild-type AKAP12 when the original
images showed positive signal
confocal microscopic images of
melanocytes in Figure 6H of Nucleic
Acids Res. 2016 by inserting blank
image panels to falsely represent the
absence of nuclear localization of
XPA, AKAP12, and ATR–pS435 in
unirradiated cells transfected with
mutant AKAP12 when the original
images showed positive signal
confocal microscopic images of
melanocytes in Figure 5A of Sci. Rep.
2017, by inserting blank image panels
in the top row, panels 1 and 4, to
falsely represent negative control
experiments, and the quantification
reported in Figure 5B that was
derived from falsified and/or
fabricated images in Figure 5A
confocal microscopic images of
melanocytes in Figure 1A, top row,
panels 1, 3, 5, and 7, of JBC 2018, by
inserting blank image panels to
represent negative control
experiments, and the quantification in
Figure 1B that was derived from
falsified and/or fabricated images in
Figure 1A
confocal microscopic images of
melanocytes in Figure 2B of JBC 2018
by using two different cells from the
same source image to falsely represent
different experimental results: a cell
for control conditions (top row, panel
1) and another cell to represent the
outcome of the treatment conditions
(top row, panel 8), as well as the
quantification reported in Figure 2C
that was derived from falsified and/or
fabricated images in Figure 2B
confocal microscopic images of
melanocytes in Figure 3D of JBC 2018
by using two different cell images
from the same source image to falsely
represent different experimental
results in: XPA–K215Q transfected
cells without forskolin (column 3,
rows 1 and 2 of lower right set of
panels) and XPA–K215Q transfected
cells with forskolin (column 4, rows
1 and 2 of lower right set of panels),
and the quantification reported in
Figure 3D that was derived from
falsified and/or fabricated images in
Figure 3D
confocal microscopic images of
melanocytes in JBC 2018 Figure 3D,
column 1, rows 1 and 2, of ‘‘XPA–
WT’’ set of panels, and in JBC 2018
Figure 3D, column 1, rows 1 and 2, of
‘‘XPA–K63Q’’ set of panels, by using
the same image field to represent UV
untreated cells ‘‘XPA–WT’’ and
‘‘XPA–K63Q’’ mutant, and the
quantification reported in Figure 3D
VerDate Sep<11>2014
17:49 Aug 10, 2022
Jkt 256001
that was derived from falsified and/or
fabricated images in Figure 3D
• confocal microscopic images of
melanocytes in Figure 2D (images in
column 1, rows 1 and 3) of Mol. Cell
2014 by reusing, manipulating, and
relabeling an image to falsely
represent the absence of [6–4]–PP in
both vehicle-treated cells and
forskolin-treated cells in negative
control experiments
• confocal microscopic images of
melanocytes in Figure 7C of Mol. Cell
2014 (and in Figure 2F of R01
CA207312–01, Figure 5A of R01
CA131075–06, and Figure 3B of R01
CA131075–06A1), by inserting blank
image panels to falsely represent
forskolin-treated cells and untreated
cells without UV exposure, and the
quantification reported in Figure 7C
and Figure 5A of R01 CA131075–06
that was derived from falsified and/or
fabricated images in Figure 7C
• confocal microscopic images of
melanocytes in Figure 4E of R01
CA131075–06A1 and Figure 4C of
R01 CA207312–01 by using cell
images from the same source
micrograph to falsely represent
cAMP-augmented interaction between
pS435–ATR and AKAP12
The following administrative actions
have been implemented:
(1) For a period of four (4) years,
beginning on July 18, 2022, Respondent
is debarred from participating in
‘‘covered transactions’’ as defined in 42
CFR 180.200 and procurement
transactions covered under the Federal
Acquisition Regulation (48 CFR chapter
1).
(2) Respondent is prohibited from
serving in any advisory capacity to PHS
including, but not limited to, service on
any PHS advisory committee, board,
and/or peer review committee, or as a
consultant for a period of four (4) years,
beginning on July 18, 2022.
(3) In accordance with 42 CFR
93.407(a)(1) and 93.411(b), HHS will
send to the journal Molecular Cell a
notice of ORI’s findings and the need for
retraction of Mol. Cell 2014 Jun
19;54(6):999–1011; doi: 10.1016/
j.molcel.2014.05.030.
Dated: August 8, 2022.
Wanda K. Jones,
Acting Director, Office of Research Integrity,
Office of the Assistant Secretary for Health.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Cell Biology
Integrated Review Group; Cellular Signaling
and Regulatory Systems Study Section.
Date: September 26–27, 2022.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: David Balasundaram,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5189,
MSC 7840, Bethesda, MD 20892, 301–435–
1022, balasundaramd@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; NIH
Research Enhancement Award (R15) in
Oncological Sciences.
Date: September 28, 2022.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Svetlana Kotliarova, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6214,
Bethesda, MD 20892, 301–594–7945,
kotliars@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
[FR Doc. 2022–17264 Filed 8–10–22; 8:45 am]
Dated: August 8, 2022.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
BILLING CODE 4150–31–P
[FR Doc. 2022–17301 Filed 8–10–22; 8:45 am]
PO 00000
BILLING CODE 4140–01–P
Frm 00021
Fmt 4703
Sfmt 9990
E:\FR\FM\11AUN1.SGM
11AUN1
Agencies
[Federal Register Volume 87, Number 154 (Thursday, August 11, 2022)]
[Notices]
[Pages 49597-49598]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-17264]
[[Page 49597]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Findings of research misconduct have been made against Stuart
G. Jarrett, Ph.D. (Respondent), former research-track assistant
professor, Department of Toxicology and Cancer Biology and Markey
Cancer Center, University of Kentucky (UK) College of Medicine.
Respondent engaged in research misconduct under 42 CFR part 93 in
research supported by U.S. Public Health Service (PHS) funds,
specifically National Cancer Institute (NCI), National Institutes of
Health (NIH), grants R01 CA131075 and T32 CA165990, National Center for
Advancing Translational Sciences (NCATS), NIH, grant UL1 TR000117, and
National Institute of Environmental Health Sciences (NIEHS), NIH, grant
T32 ES007266. The administrative actions, including debarment for a
period of four (4) years, were implemented beginning on July 18, 2022,
and are detailed below.
FOR FURTHER INFORMATION CONTACT: Wanda K. Jones, Dr.P.H., Acting
Director, Office of Research Integrity, 1101 Wootton Parkway, Suite
240, Rockville, MD 20852, (240) 453-8200.
SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of
Research Integrity (ORI) has taken final action in the following case:
Stuart G. Jarrett, Ph.D., University of Kentucky: Based on the
evidence and findings of an investigation conducted by UK, ORI's
oversight review of UK's investigation, and additional evidence
obtained and analysis conducted by ORI during its oversight review, ORI
found that Dr. Stuart G. Jarrett, former research-track assistant
professor, Department of Toxicology and Cancer Biology and Markey
Cancer Center, UK College of Medicine, engaged in research misconduct
under 42 CFR part 93 in research supported by PHS funds, specifically
NCI, NIH, grants R01 CA131075 and T32 CA165990, NCATS, NIH, grant UL1
TR000117, and NIEHS, NIH, grant T32 ES007266.
ORI found by a preponderance of the evidence that Respondent
intentionally, knowingly, or recklessly falsified and/or fabricated
Western blot and histological image data related to mechanisms of
melanoma protection by reusing, relabeling, and manipulating images or
using blank panels to falsely report data in twenty-eight (28) figures
included in four (4) PHS-supported published papers, one (1) funded PHS
grant application, and two (2) unfunded PHS grant applications. ORI
found that these acts constitute a significant departure from accepted
practices of the relevant research community. The affected papers and
grant applications are:
PKA-mediated phosphorylation of ATR promotes recruitment of
XPA to UV-induced DNA damage. Mol. Cell 2014 Jun 19;54(6):999-1011;
doi: 10.1016/j.molcel.2014.05.030 (hereafter referred to as ``Mol. Cell
2014'').
AKAP12 mediates PKA-induced phosphorylation of ATR to enhance
nucleotide excision repair. Nucleic Acids Res. 2016 Dec
15;44(22):10711-26; doi: 10.1093/nar/gkw871 (hereafter referred to as
``Nucleic Acids Res. 2016''). Retraction in: Nucleic Acids Res. 2020
Nov 18; 48(20):11814; doi: 10.1093/nar/gkaa984.
Sirtuin 1-mediated deacetylation of XPA DNA repair protein
enhances its interaction with ATR protein and promotes cAMP-induced DNA
repair of UV damage. J. Biol. Chem. 2018 Dec 7; 293(49): 19025-37; doi:
10.1074/jbc.RA118.003940 (hereafter referred to as ``JBC 2018'').
Retraction in: J. Biol. Chem. 2021 Jan-Jun;296:100185; doi: 10.1016/
j.jbc.2020.100185.
The melanocortin signaling cAMP axis accelerates repair and
reduces mutagenesis of platinum-induced DNA damage. Sci. Rep. 2017 Sep
15;7(1):11708; doi: 10.1038/s41598-017-12056-5 (hereafter referred to
as ``Sci. Rep. 2017''). Retraction in: Sci. Rep. 2021 Jan 7;11(1):847;
doi: 10.1038/s41598-020-80467-y.
R01 CA131075-06, ``Defining the contribution of ATR to MC1R-
enhanced DNA repair in melanocytes,'' submitted to NCI, NIH, on July 1,
2014 (not funded).
R01 CA131075-06A1, ``Defining the contribution of ATR to MC1R-
enhanced DNA repair in melanocytes,'' submitted to NCI, NIH, on March
2, 2015, Funded Project Dates: July 1, 2010-March 31, 2022.
R01 CA207312-01, ``Defining mechanisms of MC1R-enhanced
nucleotide excision repair in melanocytes,'' submitted to NCI, NIH, on
October 1, 2015 (not funded).
Specifically, ORI found by a preponderance of the evidence that
Respondent engaged in research misconduct by intentionally, knowingly,
or recklessly falsifying and/or fabricating:
Western blot images in Figures 7D and 7E of Mol. Cell 2014 by
reusing, manipulating, and relabeling an image to falsely represent
different experiments in UV-untreated cells in Figure 7D and in UV-
treated cells in Figure 7E
Western blot images in Supplemental Figure 3C of Mol. Cell.
2014 by reusing, manipulating, and relabeling a blot panel image to
falsely represent different experiments involving [6-4]-photoproducts
and XPA
confocal microscopic images of melanocytes in Figure 1C of
Nucleic Acids Res. 2016 by inserting a blank image panel to falsely
represent the absence of proximity ligation assay (PLA) signal in a
negative control experiment when the original image showed PLA signal
confocal microscopic images of melanocytes in Figure 5B of
Nucleic Acids Res. 2016, by inserting blank image panels to falsely
represent UV-untreated control experiments, and the quantification
reported in Figure 5C that was derived from falsified and/or fabricated
images in Figure 5B
confocal microscopic images of melanocytes in Figure 6A of
Nucleic Acids Res. 2016, by inserting blank image panels to falsely
represent the absence of PLA signal in negative control experiments
when the original images showed PLA signal, and the quantification
reported in Figure 6C that was derived from falsified and/or fabricated
images in Figure 6A
confocal microscopic images of melanocytes in Figure 6B of
Nucleic Acids Res. 2016, by inserting blank image panels to falsely
represent UV-untreated control experiments, and the quantification
reported in Figure 6C that was derived from falsified and/or fabricated
images in Figure 6B
confocal microscopic images of melanocytes in Figure 6D of
Nucleic Acids Res. 2016, by inserting blank image panels to falsely
represent no PLA signal in control experiments when the original images
showed PLA signal, and the quantification reported in Figure 6F that
was derived from falsified and/or fabricated images in Figure 6D
confocal microscopic images of melanocytes in Figure 6E of
Nucleic Acids Res. 2016, by inserting blank image panels to falsely
represent UV-untreated control experiments, and the quantification
reported in Figure 6F that was derived from falsified and/or fabricated
images in Figure 6E
confocal microscopic images of melanocytes in Figure 6G of
Nucleic Acids Res. 2016 by inserting blank image panels to falsely
represent the
[[Page 49598]]
absence of nuclear localization of XPA, AKAP12, and ATR-pS435 in
unirradiated cells transfected with wild-type AKAP12 when the original
images showed positive signal
confocal microscopic images of melanocytes in Figure 6H of
Nucleic Acids Res. 2016 by inserting blank image panels to falsely
represent the absence of nuclear localization of XPA, AKAP12, and ATR-
pS435 in unirradiated cells transfected with mutant AKAP12 when the
original images showed positive signal
confocal microscopic images of melanocytes in Figure 5A of
Sci. Rep. 2017, by inserting blank image panels in the top row, panels
1 and 4, to falsely represent negative control experiments, and the
quantification reported in Figure 5B that was derived from falsified
and/or fabricated images in Figure 5A
confocal microscopic images of melanocytes in Figure 1A, top
row, panels 1, 3, 5, and 7, of JBC 2018, by inserting blank image
panels to represent negative control experiments, and the
quantification in Figure 1B that was derived from falsified and/or
fabricated images in Figure 1A
confocal microscopic images of melanocytes in Figure 2B of JBC
2018 by using two different cells from the same source image to falsely
represent different experimental results: a cell for control conditions
(top row, panel 1) and another cell to represent the outcome of the
treatment conditions (top row, panel 8), as well as the quantification
reported in Figure 2C that was derived from falsified and/or fabricated
images in Figure 2B
confocal microscopic images of melanocytes in Figure 3D of JBC
2018 by using two different cell images from the same source image to
falsely represent different experimental results in: XPA-K215Q
transfected cells without forskolin (column 3, rows 1 and 2 of lower
right set of panels) and XPA-K215Q transfected cells with forskolin
(column 4, rows 1 and 2 of lower right set of panels), and the
quantification reported in Figure 3D that was derived from falsified
and/or fabricated images in Figure 3D
confocal microscopic images of melanocytes in JBC 2018 Figure
3D, column 1, rows 1 and 2, of ``XPA-WT'' set of panels, and in JBC
2018 Figure 3D, column 1, rows 1 and 2, of ``XPA-K63Q'' set of panels,
by using the same image field to represent UV untreated cells ``XPA-
WT'' and ``XPA-K63Q'' mutant, and the quantification reported in Figure
3D that was derived from falsified and/or fabricated images in Figure
3D
confocal microscopic images of melanocytes in Figure 2D
(images in column 1, rows 1 and 3) of Mol. Cell 2014 by reusing,
manipulating, and relabeling an image to falsely represent the absence
of [6-4]-PP in both vehicle-treated cells and forskolin-treated cells
in negative control experiments
confocal microscopic images of melanocytes in Figure 7C of
Mol. Cell 2014 (and in Figure 2F of R01 CA207312-01, Figure 5A of R01
CA131075-06, and Figure 3B of R01 CA131075-06A1), by inserting blank
image panels to falsely represent forskolin-treated cells and untreated
cells without UV exposure, and the quantification reported in Figure 7C
and Figure 5A of R01 CA131075-06 that was derived from falsified and/or
fabricated images in Figure 7C
confocal microscopic images of melanocytes in Figure 4E of R01
CA131075-06A1 and Figure 4C of R01 CA207312-01 by using cell images
from the same source micrograph to falsely represent cAMP-augmented
interaction between pS435-ATR and AKAP12
The following administrative actions have been implemented:
(1) For a period of four (4) years, beginning on July 18, 2022,
Respondent is debarred from participating in ``covered transactions''
as defined in 42 CFR 180.200 and procurement transactions covered under
the Federal Acquisition Regulation (48 CFR chapter 1).
(2) Respondent is prohibited from serving in any advisory capacity
to PHS including, but not limited to, service on any PHS advisory
committee, board, and/or peer review committee, or as a consultant for
a period of four (4) years, beginning on July 18, 2022.
(3) In accordance with 42 CFR 93.407(a)(1) and 93.411(b), HHS will
send to the journal Molecular Cell a notice of ORI's findings and the
need for retraction of Mol. Cell 2014 Jun 19;54(6):999-1011; doi:
10.1016/j.molcel.2014.05.030.
Dated: August 8, 2022.
Wanda K. Jones,
Acting Director, Office of Research Integrity, Office of the Assistant
Secretary for Health.
[FR Doc. 2022-17264 Filed 8-10-22; 8:45 am]
BILLING CODE 4150-31-P